O bjective. The Look AHEAD (Action for Health in Diabetes) study is a 16-centre randomised clinical trial in overweight and obese individuals with type 2 diabetes, designed to evaluate the long-term effects (up to 11.5 years) of intensive weight loss intervention on the time to incidence of major cardiovascular events.
Introduction
Look AHEAD (Action for Health in Diabetes) study is a randomised clinical trial being conducted in 16 centers in the US. The purpose of the Look AHEAD study is to determine whether cardiovascular morbidity and mortality in persons with type 2 diabetes can be reduced through an intensive lifestyle intervention aimed at producing and maintaining weight loss. Briefly, the intensive lifestyle intervention includes moderate-intensity physical activity to achieve and sustain at least 200 minutes per week of exercise together with a healthy diet that includes portion-controlled foods. 1 The goal of this intervention is for individuals to achieve and maintain at least 10% loss of body weight. Failure to meet appropriate goals is followed by the option of initiating other 'toolbox' strategies (e.g. medication for weight loss or behavioural contracts). The intensive lifestyle intervention is delivered over four years and participants are followed for up to 11.5 years. The control condition is termed "Diabetes Support and Education" and is comprised of occasional group meetings to provide social support and education regarding diabetes management. All participants continue to receive medical management of their diabetes from their usual source of medical care (not from the Look AHEAD medical staff). The design and methods for this trial have been described fully elsewhere. 2 This report presents the baseline demographic and biomedical characteristics of the Look AHEAD participants that were measured at entry. We compared the Look AHEAD participants to those in the general US population, using data from the National Health and Nutrition Examination Survey (NHANES) III and the National Health and Nutrition Examination Survey 1999-2000. 3, 4 Research design and methods Participants Individuals were recruited from a variety of sources, including informational mailings, open screenings, advertisements and referrals from healthcare professionals. Informed consent was obtained from all participants before screening, consistent with the Helsinki Declaration and the guidelines of each centre's institutional review board. Individual consent procedures were used for each step of the study. During screening, individuals who had urgent medical conditions or values for HbA 1C , triglycerides, creatinine or blood pressure that exceeded eligibility limits could be re-screened after three months of medical care. All participants underwent a graded maximal exercise test to confirm that, if randomised to the lifestyle intervention, this could be tolerated and considered safe and also to allow development of an appropriate, individualised exercise prescription. 1, 5 The locations of the 16 field centres and the coordinating centre are shown in figure 1.
Additional inclusion criteria were age 45-74 years, which was changed to 55-74 years during the second year to increase the anticipated cardiovascular event rate, and a body mass index (BMI) > 25 kg/m 2 (> 27 kg/m 2 , if currently taking insulin). Major exclusions included HbA 1C > 11%, blood pressure > 160/100 mmHg, triglycerides > 600 mg/dL (6.77 mmol/L), inadequate control of co-morbid conditions, factors that might limit adherence to the intervention protocol or affect conduct of the trial, and underlying disease likely to limit lifespan and/or affect safety of the interventions. It was anticipated that 20-30% of subjects enrolled would have pre-existing cardiovascular disease and that fewer than 30% would be taking insulin at entry into the study. The goal was to recruit equal numbers of men and women and to have 33% of the participants from racial and ethnic minority groups.
All study participants were required to complete a twoweek run-in period prior to randomisation which required successful self-monitoring of diet and physical activity.
Procedures
Blood samples were collected and processed at baseline according to protocol. Each Look AHEAD clinical site followed the standardised manual of operations. 1,2 Whole-blood samples for HbA 1C analysis were shipped to the Look AHEAD Central Biochemistry Laboratory (Northwest Lipid Research Laboratories, University of Washington, Seattle, WA, US) by overnight express within 24 hours of sample collection. Other serum and plasma samples were stored at < 20°C for a few days and then shipped on dry ice in batches to the central laboratory.
Standardised interviewer-administered questionnaires were used to obtain self-reported data on personal medical history, employment, education, family income, prior pregnancies, smoking, prescription medications, alcohol use and 8 In participants with triglycerides > 4.5 mmol/L, the lipoprotein fractions were separated by preparative ultracentrifugation of plasma. 9 Aliquots of serum and plasma samples were collected and stored frozen at -70°C for future analyses. Data are presented as mean + SD.
Data management and analyses
Locally generated data from each participant were entered into an internet-based data entry system by certified staff at each clinical site. The system checked for allowed ranges and internal consistency at the time of data entry; further checks were conducted in batches by the Look AHEAD Coordinating Center (CoC). Data from the central resource units (the Biochemistry Laboratory and the ECG reading centre) were transferred electronically to the CoC. The central database was maintained, and all analyses were performed, at the CoC using the Statistical Analysis System (SAS Institute, Cary, NC). Baseline characteristics of randomised participants were examined by treatment group assignment, gender and race/ethnicity (Caucasian, African-American, Hispanic, American Indian, Asian-American, and other). Comparisons of the prevalence of medication use across race/ethnicity, The total number of men in this table is 7 fewer than in table 1 because race was not specified by these 7 individuals age, education and income categories were made after adjustment for these characteristics using logistic regression. Look AHEAD data were also compared with the weighted NHANES III (1988) (1989) (1990) (1991) (1992) (1993) (1994) and NHANES 1999-2000 data for those participants matching the major eligibility criteria. 3, 4 Results
Clinical and demographic characteristics
More than 27,000 individuals underwent screening across the study centres between July 2001 and April 2004. Of these, 5,145 people were ultimately randomised, with 2,570 participants in the intensive lifestyle intervention cohort and 2,575 in the diabetes support and education cohort. Table 1 shows the overall distribution of baseline characteristics of the participants in Look AHEAD by treatment group assignment. The overall mean (+ SD) age at randomisation was 59+6.8 years. Nearly 60% of the participants were women and nearly 40% of the participants belonged to a US minority racial or ethnic group; 63.3% were White, 15.6% African-American, 13.2% Hispanic, 5.0% American Indian and 1.0% Asian-American (table 2) . Fewer than 2% reported another race group, more than one race, or did not respond to this question (referred to as 'other'). On all of the other variables, including body composition, diabetes control, plasma lipid levels, blood pressure, duration of diabetes mellitus, fitness, prevalence of the metabolic syndrome and family history of diabetes mellitus, the groups were well matched. Table 2 shows the distribution of demographic and socioeconomic characteristics of the Look AHEAD participants by gender. The females were younger than the males, with 35.9% of females versus 25.1% of males being 45-55 years old and 14.0% of females and 21.3% of males being 66-76 years old. While 60% of the overall cohort was female, there were many more females in the minority groups (e.g. 76% of the African-American participants were female). More than 80% of the males and 65% of the females were employed. The educational level was high, with more than 50% of the men and 33.5% of the women having more than 16 years in school. Alcohol intake in the past year was reported by just under 60% of the population, with its prevalence higher in males than females (70.6% to 52.2%). Family income was higher among the men, with over 40% reporting an income >$80,000/year compared with just under 20% for the women. Nearly 60% of the women and 37.6% of the men had never smoked, and just over 4% were currently smoking. Over 83% of the men and 56.6% of the women were married or living in a marriage-like relationship.
Clinical characteristics of the Look AHEAD participants, divided by gender and racial/ethnic group, are shown in tables 3 and 4. There were relatively few Asian-American men (n=16) and women (n=34). The frequency of prior pregnancy ranged between 85.8% and 94.8%, except in the Asian-American women where it was 73.5%. Caucasian participants were generally the oldest participants in the cohort, and American Indians, the youngest. Similar percentages of women and men were obese (BMI > 30 kg/m 2 ), and more than 25% of the women, except Hispanic and Asian-American women, had a BMI > 40 kg/m 2 . Among the men, fewer than 20% had a BMI > 40 kg/m 2 . Blood pressure was generally within normal limits for all groups, as required by the protocol, with approximately 75% of the subjects taking antihypertensive medication. Fasting glucose was similar for all gender ethnic groups, averaging over 150 mg/dL (8.3 mmol/L), except African-American and Asian-American men and women in whom it averaged between 141 and 147 mg/dL (7.80 and 8.15 mmol/L) . About one quarter of men and women had an HbA 1C < 6.5%. Only a small number (8% overall) had HbA 1C values that were > 9%.
Total cholesterol, LDL cholesterol and HDL cholesterol were higher in the women than the men, but triglycerides were lower. Triglycerides were considerably lower in African-Americans and Asian-American women than in other groups. American Indians had, on average, lower lipid values than other ethnic groups; however, they were also younger. Among the men, 34.5% to 60.2% across the different ethnic groups were taking lipid-lowering medications, Key: ACE = angiotensin-converting enzyme "Other" race is not presented separately due to small sample size; however, other is included in the "All" column. P value is adjusted for age, gender and education Glucose lowering
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More than 90% of this sample had the metabolic syndrome as defined by the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III criteria. 10 A high waist circumference, prevalence of hypertension > 80% and diabetes (present in all participants) were responsible for the high prevalence of this syndrome. Triglycerides > 150 mg/dL (1.70 mmol/L) were observed in only 52% of the participants. A low HDL cholesterol was present in 64% (not shown).
Overall, 14.0% of the participants reported a history of cardiovascular disease (CVD). CVD was more common in the men (21.3%) than the women (9.2%). More than 6% reported having had a myocardial infarction, with men being three times as likely as women (10.8% vs. 3.5%) (not shown) to fall into this category. Just over 2% of the population reported a history of a cerebrovascular accident (stroke) at baseline, with an equal distribution between the sexes. However, a history of coronary artery bypass grafting and/or percutaneous transluminal coronary angioplasty was again more than three times as high in the men as in the women.
Medication use
Baseline medications by race/ethnic group are shown in table 5 and by race/ethnic group and gender in figures 2 and 3. More than 80% of this population were taking one or more glucose-lowering medicines, and just under half of the group were taking two or more glucose-lowering medicines (41.1% to 48.0%). Metformin was the most frequently (48.7% to 62.0%) used drug, though it was used less often in those over 70 years of age (40.5% versus > 50% for younger age groups, table 6). It was used similarly by people of all education levels (table 7) but was used less frequently in those with the lowest income (table 8) . Sulphonylureas were used only slightly less frequently (43.8% to 52.0%) than metformin; they were used less frequently among those with more education and higher income (tables 7 and 8). Thiazolidinediones were used by a smaller number (15.1% to 28.1%) and insulin by an even smaller number again (13.9% to 18.6%). For each of these drugs there was a gradient across education/income levels. Insulin was used a third less often in the upper income/education group and thiazolidinediones nearly 50% more often. There was no difference by age (table 6) .
Lipid-lowering drugs were used by 26.0% to 55.0% of the participants. Statins were the drugs most commonly used in this class. There was greater use of this class of drugs in those subgroups with more education, higher income and older age. Antihypertensive drugs were used by 66.0% to 80.2% (table 5). Among this group of drugs, angiotensin-converting enzyme inhibitors (ACEIs) were used more than diuretics (range for ACEIs 32.0 to 47.7% compared to range for diuretics 18.0 to 39.7%). Calcium channel blockers (CCBs) were used less than beta-blockers (10.8 to 26.7% against 7.4 to 20.5%). Angiotensin receptor blockers (ARBs) were the least frequently used class of antihypertensive drugs (9.6 to 24.0%) 209 VOLUME 3 ISSUE 3 . DECEMBER 2006 (table 5 ). The use of CCBs, ARBs and ACEIs was positively associated with age. However, among these three antihypertensive drug classes, there was no gradient by income or educational level (except for ARBs, the use of which was associated with increasing education). Antidepressants were used by 16.5% of the participants. Use was higher in younger participants (20.1%) and lowest in those over age 70 (9.9%) (table 6) . Aspirin was used daily by 31.9 to 50.4% of the population and on some days by 2.0 to 12.0%, meaning that a significant number of participants with diabetes in this trial were not taking aspirin (45% overall). There was a higher use of aspirin in those with more education, higher income and greater age (tables 6-8, figures 4-6) .
The Look AHEAD population compared to the NHANES III and NHANES 1999-2000 samples of persons with diabetes To compare the Look AHEAD participants with the general US population, we examined the characteristics of the NHANES III and NHANES 1999-2000 participants -a representative sample of the US population (table 9 ). These NHANES samples had self-reported diabetes and were also defined by the same age and BMI criteria as those required for participation in Look AHEAD. The Look AHEAD participants are younger, with only 17% aged 66-76 years, compared to more than 30% in the two NHANES samples of persons with diabetes. The proportion of women was modestly higher in Look AHEAD (59.5% compared with approximately 50%). The difference in the proportion of racial/eth-nic minorities with diabetes between the two NHANES evaluations is evident, with proportionally more Hispanics and fewer Whites in the later survey. The Look AHEAD participants had a similar ethnic distribution to that of NHANES 1999-2000. BMI was significantly higher in the Look AHEAD participants, as required by the protocol for enrolment. Significant trends for improvement in education were evident between NHANES III and NHANES 1999-2000. 4 Look AHEAD participants were better educated (80.1% > 12 years of education against 34.9% for the NHANES 1999-2000 sample). Participants in Look AHEAD were less likely to smoke than the general population of persons with diabetes (4.4% versus 16.2%), suggesting that there was a self-selection bias among volunteers for Look AHEAD. Significant temporal trends for improvement in lipid levels in the general population from NHANES surveys 4 and in these two diabetic subgroups is evident for all classes of lipids. Lipid levels were somewhat better in the Look AHEAD participants compared to NHANES III, but were similar to those in NHANES 1999-2000. Fasting plasma glucose concentrations and HbA 1C both improved between NHANES III and NHANES 1999-2000, but glucose and HbA 1C values were even lower in Look AHEAD than in the representative sample from NHANES of persons with diabetes, suggesting that the severity of the diabetes or the quality of control differed. In summary, with the exception of obesity, the Look AHEAD cohort is healthier, and consequently at less risk for CVD, than the general population of persons with diabetes in the US. 
Discussion
The primary outcome of the Look AHEAD study is the development of cardiovascular disease or death. Secondary outcomes include components of cardiovascular disease risk, cost and cost-effectiveness, diabetes control and complications, hospitalisations, intervention processes and the quality of life. The Look AHEAD study was designed with an intentionto-treat analysis plan. 2 The final sample size (5,145 participants) will provide > 90% power to detect an 18% reduction in the rate of primary outcomes among participants assigned to the lifestyle intervention with a 5% level of significance (two-sided), after adjustment for losses to follow-up. 2 This assumes a rate of 3.125% per year in the development of primary outcomes in those assigned to the Diabetes Support and Education Control group. Participants were randomised over a 2.5-year period and are to be followed for up to 11.5 years. To protect participant welfare, interim results are reviewed by a data and safety monitoring board. 2 The study is scheduled to complete participant follow-up in December 2012.
Our predetermined target was to include > 33% of participants from US minority ethnic and racial groups, and 37% of the Look AHEAD cohort met those criteria. The remaining 63%, self-identified as White, probably represent a varied pool of individuals with ancestry from Europe as well as western Asia and the Middle East. The heterogeneity of the US minority subgroups should also be noted, because the African-American designation included people of Afro-Caribbean descent, and the term "Hispanic" includes individuals from Latin America and the Caribbean without regard to racial admixture. American Indian participants in Look AHEAD are concentrated in the Southwest because three centres recruited exclusively from regional tribes; small numbers of American Indian participants were randomised in other centres. Asian-Americans in Look AHEAD included participants descended from Japanese, Chinese, other East Asian groups, Asian Indians and Pacific Rim Australasian populations.
As the study is aimed at determining whether CVD events can be reduced by lifestyle intervention in persons with diabetes, it is not surprising that risk factors for coronary heart disease were highly prevalent in the Look AHEAD cohort. Fourteen percent had a history of CVD, which was higher for men than women. A history of and/or treatment for hypertension was present in 84% of individuals. Dyslipidaemia was present in a large proportion of participants. More than 56% of men and 43% of women reported a history of and/or treatment for high cholesterol. When comparing the two representative samples of persons with diabetes from the general VOLUME 3 ISSUE 3 . DECEMBER 2006 211 Data are expressed as percentage of each income group population in NHANES III and NHANES 1999-2000 and the Look AHEAD samples, two conclusions are obvious. First, lipid values have improved in the samples from persons with diabetes, just as they have in the temporal data from NHANES samples for the broader population. 5 Second, even though the Look AHEAD cohort is more obese with a higher BMI, lipid profiles are more favorable than the NHANES samples from persons with diabetes. Based on baseline characteristics, 94% of the cohort is classified as having the metabolic syndrome using the criteria proposed by the NCEP ATP III panel. 10 Look AHEAD selected participants who were overweight (BMI > 25 kg/m 2 ). Its cohort has many obese individuals: BMI was > 40 kg/m 2 in 18% of men and 25% of women. This far exceeds the proportion seen in the general population, where only 5% of men and 14% of women have a BMI > 40 kg/m 2 . 11 Diabetes is considered a "cardiovascular risk equivalent" 12 because the rate of first myocardial infarction and stroke is as high as the rate in age-and sex-matched people who have already had their first myocardial infarction. Among the recommendations for persons with diabetes is the use of low-dose aspirin, 13 yet in the Look AHEAD study population nearly 50% of most ethnic groups reported ORIGINAL ARTICLE
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DIABETES AND VASCULAR DISEASE RESEARCH never using aspirin. More than 83% of each ethnic group were taking antidiabetic drugs, and approximately 40% were taking more than one of these drugs. The most common antidiabetic drug was metformin, with sulphonylureas used almost as frequently. In Whites and African-Americans insulin was used half as much as thiazolidinediones, whereas in the other groups they were used equally or insulin was used more often (American Indians). Use of antihypertensives was common, with 23 to 44% taking more than one drug in this class. Lipid-lowering agents were used by nearly 50%, with statins being the predominant drug category. Finally, depression is more common in persons with diabetes than in the general population, 14, 15 and this may account for the 8 to 20% who were taking antidepressant drugs. However, this is a considerably higher figure than the 5.7% reported for the baseline population in the Diabetes Prevention Program. 16 Clearly, the Look AHEAD population is a population with a high frequency of medication use at baseline.
In conclusion, the data obtained at baseline in the participants randomised to participate in the Look AHEAD study indicate that the study has recruited a cohort comprising individuals of a broad age range who are representative of groups in the United States. By virtue of the fact that the cohort has a variety of metabolic characteristics associated with type 2 diabetes and CVD, including obesity, dyslipidaemia and hypertension, it appears appropriate to test the primary study question as to whether lifestyle intervention is able to reduce CVD events in individuals with type 2 diabetes. These participants represent a cohort comprising older individuals as well as subjects from US minority racial/ethnic groups who have a high prevalence of type 2 diabetes. The participants have a variety of metabolic risk factors associated with type 2 diabetes and CVD, which put them at risk for cardiovascular events and death. Look AHEAD will determine whether lifestyle interventions designed to promote and sustain weight loss have an impact on reducing these outcomes.
